US Patent 11590207 Dosage regimen for a controlled-release PTH compound
Patent 11590207 was granted and assigned to Ascendis Pharma on February, 2023 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
September 28, 2017
Date of Patent
February 28, 2023
Patent Applicant
Patent Application Number
16337713
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 11590207 Dosage regimen for a controlled-release PTH compound
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
